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Abstract: The role of sodium in hypertension remains unresolved. Although genetic factors have
a significant impact on high blood pressure, studies comparing genetic susceptibility between
people with low and high sodium diets are lacking. We aimed to investigate the genetic variations
related to hypertension according to sodium intake habits in a large Korean population-based
study. Data for a total of 57,363 participants in the Korean Genome and Epidemiology Study Health
Examination were analyzed. Sodium intake was measured by a semi-quantitative food frequency
questionnaire. We classified participants according to sodium intake being less than or greater
than 2 g/day. We used logistic regression to test single-marker variants for genetic association with
a diagnosis of hypertension, adjusting for age, sex, body mass index, exercise, alcohol, smoking,
potassium intake, principal components 1, and principal components 2. Significant associations were
defined as p < 5 × 10−8. In participants whose sodium intake was greater than 2 g/day, chromosome 6
open reading frame 10 (C6orf10)-human leukocyte antigen (HLA)-DQB1 rs6913309, ring finger protein
(RNF)213 rs112735431, glycosylphosphatidylinositol anchored molecule-like (GML)- cytochrome P450
family 11 subfamily B member 1(CYP11B1) rs3819496, myosin light chain 2 (MYL2)-cut like homeobox
2 (CUX2) rs12229654, and jagged1 (JAG1) rs1887320 were significantly associated with hypertension.
In participants whose intake was less than 2 g/day, echinoderm microtubule-associated protein-like
6(EML6) rs67617923 was significantly associated with hypertension. Genetic susceptibility associated
with hypertension differed according to sodium intake. Identifying gene variants that contribute to
the dependence of hypertension on sodium intake status could make possible more individualized
nutritional recommendations for preventing cardiovascular diseases.
Keywords: sodium intake; hypertension; single-nucleotide polymorphism
1. Introduction
Sodium is the most important electrolyte for maintaining extracellular fluid volume and regulating
cellular membrane potential [1]. The importance of dietary sodium in regulating blood pressure (BP)
has received much attention in the past. Hypertension has been the most important global risk factor
for all-cause mortality and for cardiovascular mortality [2]. Many studies have demonstrated the
association of sodium consumption with hypertension and risk of cardiovascular diseases (CVD) [3–5].
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Therefore, the World Health Organization (WHO) recommends sodium intake of less than 2 g/day to
reduce BP and the risk of CVD [6].
Under normal physiological adaptation to sodium intake, the pressure natriuresis curve is
regulated by the renin–angiotensin system and renal sympathetic nerve activity [7]. Increased sodium
intake suppressed angiotensin II and led to pressure natriuresis cure shifting, which increased renal
sodium excretion [7]. Both epithelial sodium transporter and aldosterone level are also involved in
adapting the dietary sodium intake. In patients with salt-sensitive increased BP, enhanced sodium
reabsorption, changes in pressure natriuresis curve, a suppressed renin–angiotensin system, and gene
polymorphisms in voltage-dependent Ca2+ channels and sodium-bicarbonate cotransporter were
noted [8,9]. Furthermore, the levels of natriuretic peptides could be affected by excessive sodium
intake, decreased potassium and magnesium intake, and metabolic diseases such as obesity [10–12].
However, the relationship between sodium intake and BP remains unresolved. A meta-analysis
of 13 prospective studies with 177,035 participants reported that high salt intake is associated with
significantly increased risk of stroke and total CVD [3]. Another meta-analysis that included 22 trials
in hypertensive patients and 12 trials in normotensive participants reported that a salt reduction of
4.4 g/day led to a mean systolic blood pressure (SBP) change of −4.18 mm Hg (95% confidence interval
[CI] −5.18 to −3.18, I2 = 75%), and a diastolic blood pressure (DBP) change of −2.06 mm Hg (CI, −2.67 to
−1.45, I2 = 68%) [4]. Conversely, several studies reported an inverse association between sodium intake
and CVD. Stolarz-Skrzypek et al. [13] found that SBP, but not DBP, was significantly correlated with
24 h urinary sodium excretion; however, the incidence of hypertension did not increase, and CVD risk
decreased with increasing sodium excretion tertiles. Interestingly, some studies have shown a J-shaped
association between sodium intake and CVD. Martin et al. [14] showed that sodium excretion rates
greater than 7 g/day or less than 3 g/day were associated with increased risk of all CV events as well as
CVD mortality, compared to sodium excretion of 4 to 5.99 g/day, using the two-cohort data. The same
author [15] reaffirmed that estimated sodium intake of 3 to 6 g/day was associated with a low risk of
CVD among 101,945 persons in 17 countries. These conflicting findings are due not only to differences
among studies but also to the complexity of traits of hypertension. Essential hypertension, with varying
or unknown pathology, accounts for 95% of all hypertension cases [16]. High BP is known to result from
interaction among multiple factors, including genetic susceptibility, obesity, aging, sedentary life style,
alcohol consumption, high salt intake (especially in salt-sensitive persons), and low potassium intake [16].
Genetic elements were reported to make a 30–70% contribution to BP variation [17,18]. Under similar
environmental conditions, some individuals develop hypertension and others do not.
Single-nucleotide polymorphisms (SNPs), single base substitutions within the deoxyribonucleic
acid (DNA) sequence, are the most common type of human genetic variation [19]. Inter-individual
genetic variation is an important determinant of human nutritional requirements [20]. However,
studies comparing genetic susceptibility associated with hypertension between people with low versus
high sodium diets have been limited. Identifying gene variants that contribute to the association of
hypertension with sodium intake could contribute to better understanding of the pathophysiology of
hypertension, and offer opportunities to determine optimal nutrition status for individuals.
Therefore, we aimed to investigate the genetic variations involved in the relationship between
hypertension and sodium intake, in a large Korean population-based study.
2. Materials and Methods
2.1. Study Population
The Korean Genome and Epidemiology Study (KoGES) is a large cohort study to find genetic
and environmental factors, and their interactions, in non-communicable diseases, with government
funding [21]. KoGES Health Examination (KoGES_HEXA), one of the subset cohorts of KoGES, consists
of community dwellers and participants, aged ≥ 40 years at baseline recruited from the national health
examinee registry.
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In the current study, we included the total 58,701 participants who participated in KoGES_HEXA.
We excluded participants in KoGES_HEXA from the present study if values were missing for BP, body
mass index (BMI), waist circumference (WC), heart rate (HR), alcohol, smoking, or exercise (n = 1338).
A total of 57,363 participants were included in the current study. Hypertensive patients (n = 15,245)
were defined as those with SBP ≥ 140 mm Hg, DBP ≥ 90 mm Hg, or a history of hypertension or taking
antihypertensive medication. Controls (n = 42,114) were defined as those without hypertension or
taking anti-hypertensive drug or cardiovascular diseases.
Figure 1 shows a flow chart describing this study. We treated the three analyses set. In analysis
1, we compared with control (n = 42,114) and hypertension patients (n = 15,245). In analysis 2, we
compared with controls (n = 17,869) and hypertension patients (n = 6,546) in the participants with <2
g/day (n = 24,415). In analysis 3, we compared with controls (n = 24,245) and hypertension patients (n
= 8699) in the participants with ≥2 g/day (n = 32,994). The study was approved by the institutional
review board of Theragen Bio Co., Ltd. (approval number: 700062-20190819-GP-006-02).
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2.2. Assessment of Dietary Sodium and Potassium Intake and Covariates
For dietary assessment, a semi-quantitative food frequency questionnaire (FFQ) involving 103
items was developed for the KoGES. Participants reported the frequency and amount of foods eaten
over the past year. The results of the questionnaire were analyzed, with reference to a food composition
database, to estimate intakes. FFQs are widely used as the primary dietary assessment tool in
epidemiological studies [22]. We classified participants based on sodium intake, according to the WHO
recommendation of 2 g/day [6]. The WC was measured midway between the bottom rib and the iliac
crest. Body mass index (BMI) was calculated as weight (kg) divided by height (m) squared. Blood
pressures in the seated position were measured twice, using a mercury sphygmomanometer. Smoking
status was classified into three categories: non-smokers, ex-smokers and current smokers. Drinking
status was classified into three groups: non-drinkers (those who drink alcohol fewer than 12 times a
year, with one drink not exceeding one cup), ex-drinkers, and current drinkers. Exercise was defined
as regular exercise sufficient to cause perspiration.
2.3. Genotyping
Fasting blood samples were collected into one serum separator tube and two
ethylenediaminetetraacetic acid tubes. Blood DNA samples were prepared, and all samples were then
transported to the National Biobank of Korea. The SNP genotypes of participants were extracted from
the Korea Biobank array (referred to as KoreanChip), which was optimized for the Korean population
and to demonstrate findings of genome-wide association study (GWAS) of blood biochemical traits.
The KoreanChip comprised >833,000 markers, including >247,000 rare or functional variants, derived
from sequencing data for over 2500 Koreans [23]. Detailed information about the KoreanChip was
described in a previous study [23]. We applied the following criteria in the analysis of KoreanChip
data, to control the quality of genotyping results: call rate >97%, minor allele frequency >0.01, missing
genotype >0.01, Hardy-Weinberg equilibrium p > 0.000001. In addition, the genotype used in the
analysis is genome data which imputed data from a dataset of 1000 genome phase 1 and 2 Asian panels.
2.4. Statistical Analysis
The data were presented either as mean ± standard deviation or as numbers (percentage).
To compare participants with and without hypertension, we used two-tailed Student’s t-tests for
continuous variables, or chi-squared tests for categorical variables. In addition, we performed principal
component analysis (PCA) to reduce bias of genomic data according to the region where samples
were collected, and used principal component (PC)1 and PC2 as covariates in statistical analyses.
We used logistic regression to test single-marker variants for genetic association with a diagnosis of
hypertension, while adjusting for age, sex, BMI, exercise, alcohol, smoking, potassium intake, PC1 and
PC2. All statistical tests were based on an adjusted model using PLINK (ver. 1.07). p values < 5 × 10−8
were considered as statistically significant.
3. Results
3.1. General Characteristics of the Study Population
Table 1 shows the general characteristics of participant categorized according to sodium intake.
There were 24,415 (42.6%) and 32,944 (57.4%) participants with sodium intakes <2 g/day or ≥2
g/day, respectively, and with respective mean ages of 54.1 and 53.6 years. The proportion of men
was significantly higher among participants with sodium intake ≥2 g/day. SBP and DBP were also
significantly higher in this group. The mean total cholesterol (TC) and low-density lipoprotein (LDL)
cholesterol level were not different between two groups. The mean level of triglyceride (TG) was
significantly higher in participants who intake sodium intake was ≥2 g/day, while the mean level of
high-density lipoprotein (HDL) cholesterol was significantly lower in this group. The mean level of
C-reactive protein (CRP) was not different between two groups. The proportions of exercise, drinking,
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and smoking were higher among participants with sodium intake ≥2 g/day. Sodium and potassium
consumptions were significantly higher in participants with sodium intake ≥2 g/day (all p < 0.001).
The sodium to potassium (Na/K) ratio was also significantly higher in participants with sodium intake
≥2 g/day (p < 0.001). Table 1 also presents characteristics of participants subcategorized according to
the presence of hypertension (HTN). The mean age, BMI, WC, SBP, and DBP were significantly higher
in hypertensive patients than controls, whether sodium intake was <2 or ≥2 g/day. The mean TC, HDL,
LDL were significantly lower in hypertensive patients than controls, whether sodium intake was < or
≥2 g/day. The TG and CRP were significantly higher in hypertensive patients than controls, whether
sodium intake was <2 or ≥2 g/day. Among participants with sodium intake <2 g/day, sodium and
potassium intakes were lower for hypertensive patients (p = 0.038, and p < 0.001), whereas mean Na/K
was higher in hypertensive patients than in controls (p < 0.001). Among participants with sodium
intake ≥2 g/day, sodium intake was similar between hypertensives and controls (p = 0.433), while
potassium intake was significantly lower (p < 0.001) and Na/K was higher in hypertensive patients (p <
0.001) than in controls.
3.2. SNPs Associated with Hypertension Based on Sodium Intake
Table 2 shows the SNPs most strongly associated or clustered with hypertension in the Korean
subjects, according to their sodium intake. Odds ratios (OR) and 95% CIs were calculated using logistic
regression analysis after adjusting for age, sex, BMI, alcohol consumption, smoking, physical activity,
and potassium intake. SNPs rs16998073 and rs12509595 demonstrated significant association with
hypertension risk both in participants with sodium intake <2 g/day and those with intake ≥2 g/day.
SNPs rs1191582, rs11105378, and rs140473396 were significantly associated with a decreased risk of
hypertension, both in participants with sodium intake <2 g/day and those with intake ≥ 2g/day. SNP
rs67617923 was significantly associated with increased risk of hypertension only in participants with
sodium intake <2 g/day (OR = 1.294 [1.187–1.410], p = 4.29 × 10−9). SNPs rs6913309 and rs112735431
were significantly associated with hypertension only in participants with sodium intake ≥2 g/day (OR
= 1.145 [1.094–1.197], p = 4.23 × 10−9; and OR =1.706 [1.446–2.012], p = 2.38 × 10−10, respectively). SNPs
rs3819496, rs12229654, and rs1887320 were significantly associated with decreased risk of hypertension
in participants with sodium intake ≥2 g/day (OR = 0.892 [0.857–0.929], p = 3.73 × 10−8; OR = 0.834
[0.787–0.883], p = 5.25× 10−10; and OR = 0.892 [0.859–0.925], p = 1.45× 10−9, respectively). All SNPs that
were found to be significantly related to hypertension are described in the Supplementary Tables (Table
S1, SNPs significantly related to hypertension; Table S2, SNPs significantly related to hypertension
in participants with sodium intake <2 g/day; Table S3, SNPs significantly related to hypertension in
participants with sodium intake ≥2 g/day).
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Table 1. General characteristics of study population based on sodium intake and according to prevalence of hypertension.
Characteristics













(n = 8699) p
†
Age (years,) 54.05 ± 7.90 53.58 ± 8.07 <0.0001 <0.0001 0.002 52.70 ± 7.70 57.73 ± 7.25 <0.0001 52.23 ± 7.85 57.36 ± 7.44 <0.0001
Sex (male, %) 7453 (30.5) 12,348 (37.5) <0.0001 ‡ <0.0001 ‡ <0.0001 ‡ 4929 (27.6) 2524 (38.6) <0.0001 ‡ 8264 (34.1) 4084 (46.9) <0.0001 ‡
BMI (kg/m2) 24.02 ± 46.63 24.20 ± 34.68 0.606 0.743 <0.0001 23.29 ± 2.70 24.91 ± 2.92 <0.0001 23.59 ± 2.74 25.17 ± 2.95 <0.0001
WC (cm,) 80.08 ± 8.54 81.26 ± 8.65 <0.0001 <0.0001 <0.0001 78.72 ± 8.23 83.78 ± 8.29 <0.0001 79.93 ± 8.35 84.97 ± 8.40 <0.0001
SBP (mmHg) 122.14 ± 14.80 122.57 ± 14.73 0.001 <0.0001 0.042 117.57 ± 11.73 134.62 ± 15.12 <0.0001 118.07 ± 11.65 135.12 ± 15.14 <0.0001
DBP (mmHg) 75.44 ± 9.71 75.94 ± 9.72 <0.0001 <0.0001 0.001 72.89 ± 8.18 82.43 ± 10.11 <0.0001 73.42 ± 8.21 82.96 ± 10.15 <0.0001
HR (bpm) 69.30 ± 9.28 69.06 ± 9.00 0.002 0.012 0.09 68.94 ± 8.93 70.27 ± 10.11 <0.0001 68.73 ± 8.70 70.00 ± 9.74 <0.0001
TC (mg/dL) 197.19 ± 36.00 197.50 ± 35.45 0.307 0.424 0.558 197.88 ± 35.46 195.33 ± 37.35 <0.0001 198.16 ± 35.11 195.68 ± 36.30 <0.0001
TG (mg/dL) 122.06 ± 83.51 127.35 ± 87.03 <0.0001 <0.0001 0.0001 115.17 ± 77.32 140.86 ± 95.93 <0.0001 120.52 ± 82.17 146.35 ± 96.79 <0.0001
HDL-C (mg/dL) 54.23 ± 13.30 53.43 ± 13.04 <0.0001 <0.0001 <0.0001 55.05 ± 13.34 52.00 ± 12.91 <0.0001 54.23 ± 13.14 51.19 ± 12.49 <0.0001
LDL-C (mg/dL) 119.14 ± 32.36 119.40 ± 31.98 0.344 0.531 0.52 120.28 ± 31.72 116.00 ± 33.89 <0.0001 120.48 ± 31.46 116.36 ± 33.21 <0.0001
CRP (mg/dL) 0.14 ± 0.45 0.14 ± 0.34 0.333 0.432 0.639 0.13 ± 0.46 0.17 ± 0.41 <0.0001 0.13 ± 0.34 0.16 ± 0.34 <0.0001
Exercise status
Yes (%) 13,103 (53.7) 18,250 (55.4) <0.0001 ‡ <0.0001 ‡ 0.441 9422 (52.7) 3681 (56.2) <0.0001 ‡ 13,304 (54.9) 4946 (56.9) <0.0001 ‡
No (%) 11,312 (46.3) 14,694 (44.6) 8447 (47.3) 2865 (43.8) 10,941 (45.1) 3753 (43.1)
Smoking status
Non-smokers (%) 18,638 (76.3) 23,386 (71.0) <0.0001 ‡ <0.0001 ‡ <0.0001 ‡ 13,957 (78.1) 4681 (71.5) <0.0001 ‡ 17,779 (73.3) 5607 (64.5) <0.0001 ‡
Ex-smokers (%) 3484 (14.3) 5586 (17.0) 2235 (12.5) 1249 (19.1) 3562 (14.7) 2024 (23.3)
Current smokers (%) 2293 (9.4) 3972 (12.1) 1677 (9.4) 616 (9.4) 2904 (12.0) 1068 (12.3)
Drinking status
Non-drinker (%) 13,411 (54.9) 16,369 (49.7) <0.0001 ‡ <0.0001 ‡ <0.0001 ‡ 9880 (55.3) 3531 (53.9) <0.0001 ‡ 12,333 (50.9) 4036 (46.4) <0.0001 ‡
Ex-drinker (%) 921 (3.8) 1212 (3.7) 605 (3.4) 316 (4.8) 767 (3.2) 445 (5.1)
Current drinker (%) 10083 (41.3) 15363 (46.6) 7384 (41.3) 2699 (41.2) 11145 (46.0) 4218 (48.5)
Total intake energy (kcal/day) 1498.32 ± 394.32 1923.57 ± 577.56 <0.0001 <0.0001 <0.0001 1502.56 ± 397.52 1486.77 ± 385.27 0.0056 1938.06 ± 588.37 1883.05 ± 544.22 <0.0001
Sugar (g/day) 275.09 ± 74.34 335.71 ± 92.28 <0.0001 <0.0001 <0.0001 274.83 ± 74.99 275.80 ± 72.54 0.3667 337.21 ± 93.79 331.51 ± 87.81 <0.0001
Fat (g/day) 21.03 ± 10.72 32.85 ± 19.94 <0.0001 <0.0001 <0.0001 21.54 ± 10.94 19.62 ± 9.96 <0.0001 33.57 ± 20.32 30.81 ± 18.71 <0.0001
Protein (g/day) 46.51 ± 14.39 68.25 ± 27.58 <0.0001 <0.0001 <0.0001 46.83 ± 14.50 45.64 ± 14.03 <0.0001 68.90 ± 28.03 66.45 ± 26.22 <0.0001
Sugar ratio 73.48 ± 6.45 70.41 ± 7.05 <0.0001 <0.0001 <0.0001 12.53 ± 2.23 12.32 ± 2.12 <0.0001 14.12 ± 2.55 14.02 ± 2.69 <0.0001
Fat ratio 5.58 ± 2.28 6.60 ± 2.40 <0.0001 <0.0001 <0.0001 5.71 ± 2.32 5.24 ± 2.12 <0.0001 6.70 ± 2.39 6.32 ± 2.40 <0.0001
Protein ratio 12.47 ± 2.20 14.09 ± 2.59 <0.0001 <0.0001 <0.0001 73.19 ± 6.57 74.28 ± 6.05 <0.0001 70.20 ± 7.01 71.01 ± 7.12 <0.0001
Na (mg/day) 1323.39 ± 435.98 3254.94 ± 1251.19 <0.0001 <0.0001 <0.0001 1328.30 ± 433.08 1310.05 ± 443.58 0.0038 3258.11 ± 1258.90 3245.85 ± 1229.30 0.4329
K (mg/day) 1591.80 ± 561.36 2694.00 ± 1046.87 <0.0001 <0.0001 <0.0001 1607.78 ± 564.81 1548.20 ± 549.57 <0.0001 2719.81 ± 1069.77 2621.77 ± 976.41 <0.0001
Na/K ratio 0.87 ± 0.28 1.26 ± 0.34 <0.0001 <0.0001 <0.0001 0.86 ± 0.28 0.88 ± 0.29 <0.0001 1.25 ± 0.34 1.29 ± 0.35 <0.0001
Data are presented either as mean ± standard deviation or as numbers (percentage). p values are calculated by two-tail Student’s t-test † or Chi-squared test ‡. 1 The p-value comparing the
baseline characteristic between the sodium intake <2 g/day group and the sodium intake ≥2 g/day group, among all participants.2 The p-value comparing the baseline characteristic
between the sodium intake <2 g/day group and sodium intake ≥2 g/day group, among participants without HTN. 3 The p-value comparing the baseline characteristic between the sodium
intake <2 g/day group and sodium intake ≥2 g/day group, among participants with HTN. Sugar intake ratio = total sugar (gram) × 4 kcal/total energy intake (kcal) × 100; protein intake
ratio = protein (gram) × 4 kcal/total energy intake (kcal) × 100; fat intake ratio (gram) × 9 kcal/total energy intake (kcal) × 100. BMI, body mass index; WC, waist circumference; SBP,
systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; TC, total cholesterol; TG, triglyceride; HDL, high-density lipoprotein cholesterol; LDL, low density lipoprotein
cholesterol; CRP, C-reactive protein. HTN, hypertension.
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Table 2. Single-nucleotide polymorphisms (SNPs) most strongly associated with hypertension susceptibility loci in the Korean population, according to sodium intake.
SNP Chr:BP A1
MAF Gene Feature Cluster SNP * OR (95% CI) p
Present Study EAS EUR AMR
Participants with sodium intake <2 g/day
rs67617923 2:54968517 A 0.063 0.074 0.160 0.098 EML6 intron variant rs72806698; rs67246257; rs67514855 1.294 (1.187–1.410) 4.29 × 10−9
rs16998073 4:81184341 T 0.347 0.360 0.268 0.267 FGF5 upstream gene variant rs12509595; rs10857147 1.245 (1.190–1.302) 1.14 × 10−21
rs11191582 10:104913653 A 0.227 0.265 0.089 0.193 NT5C2 intron variant rs11191479; rs11191484; rs72050190; rs145010450; rs10883815 0.849 (0.806–0.895) 1.08 × 10−9
rs11105378 12:90090741 T 0.372 0.310 0.141 0.112 ATP2B1–LINC00936 intergenic region rs2681485; rs7136259; rs11105377; rs1401982; rs1689040 0.874 (0.836–0.915) 4.67 × 10−9
Participants with sodium intake ≥2 g/day
rs12509595 4:81182554 C 0.347 0.361 0.267 0.267 PRDM8–FGF5 intergenic region rs16998073; rs10857147 1.228 (1.181–1.277) 7.46 × 10−25
rs6913309 6:32339840 A 0.212 0.139 0.310 0.244 C6orf10–HLA-DQB1 upstream gene variant N/A 1.145 (1.094–1.197) 4.23 × 10−9
rs112735431 17:78358945 A 0.011 0.002 0.000 0.000 RNF213 missense variant rs138309870 1.706 (1.446–2.012) 2.38 × 10−10
rs3819496 8:143923891 G 0.312 0.321 0.421 BP0.442 GML–CYP11B1 intron variant rs3753123; rs143247792; rs4527848; rs4606038; rs28524031 0.892 (0.857.0.929) 3.73 × 10−8
rs140473396 10:104795885 GAC 0.247 0.285 0.097 0.197 CNNM2–NT5C2 intron variant rs11191479; rs11191484; rs72050190; rs145010450; rs10883815 0.836 (0.800–0.873) 1.11 × 10−15
rs12229654 12:111414461 G 0.141 0.159 0.000 0.000 MYL2–CUX2 intergenic region rs149607519; rs148177611; rs2188380; rs12227162 0.834 (0.787–0.883) 5.25 × 10−10
rs1887320 20:10965998 G 0.478 0.540 0.461 0.264 JAG1 intergenic region rs6108787; rs1327235; rs6108789; rs913220 0.892 (0.859–0.925) 1.45x10−9
SNP, single-nucleotide polymorphism; Chr, chromosome; BP, base pair; EAS, East Asian; EUR, European; AMR, American; N/A, not applicable; MAF, major allele frequency; A1, minor
allele; OR, odds ratio; 95% CI, 95% confidence interval. * The cluster SNP is the top five SNPs with an R2 value of 0.8 or higher, and within a ±200 kb range.
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A Miami plot shows p-values for the SNP associations with hypertension in participants whose
sodium intake was either <2 g/day or ≥2 g/day (Figure 2).
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4. Discussion
This study identified both shared loci and sodium intake-specific loci related to hypertension.
Fibroblast growth factor 5 (FGF5), PR domain zinc finger protein 8(PRDM8)-FGF5, 5’-nucleotidase,
cytosolic II(NT5C2), ATPase plasma membrane Ca2+ transporting 1(ATP2B1), long intergenic
non-protein coding RNA 936(LINC00936), and cyclin and CBS domain divalent metal cation transport
mediator 2(CNNM2)-NT5C2 were commonly identified loci both in participants whose intakes
were less than 2 g/day and in those with intakes greater than 2 g/day. Chromosome 6 open
reading frame 10(C6orf10), human leukocyte antigen (HLA)-DQB1, ring finger protein (RNF)213,
glycosylphosphatidylinositol anchored molecule-like (GML), cytochrome P450 family 11 subfamily B
Member 1(CYP11B1), myosin light chain 2 (MYL2), cut like homeobox 2 (CUX2), and jagged1(JAG1)
were significantly associated with hypertension in participants whose sodium intake was greater than
2 g/day, while loci in echinoderm microtubule-associated protein-like 6 (EML6) were significantly
associated with hypertension in participants whose sodium intake was less than 2 g/day.
Guyton [24] established that long-term elevation of blood pressure is caused by vasoconstriction
including the renal arteries or excess sodium retention through the kidney. The role of the kidney in BP
control had been discovered by hypotension or hypertension caused by gene mutations which affect
net renal sodium reabsorption [25]. For example, the loss of function mutations of the thiazide-sensitive
NaCl symporter (e.g., Gitelman syndrome) impairs sodium reabsorption in the distal convoluted
tubes and this results in a loss of sodium, potassium, and magnesium and a decrease in BP [25].
Enhanced tubular reabsorption of salt is important in the pathogenesis of obesity-related hypertension
by regulating phosphorylation of Na+-K+-2Cl− cotransporter and regulation of STE20/SPS1-related
proline/alanine-rich kinase (SPAK)/oxidative-stress-responsive kinase-1 (OSR1) by AMP-activated
protein kinase [26]. Recently, it was discovered that genetic variations at a number of loci increases
susceptibility to hypertension in the context of environmental exposures through a variety of
physiological mechanisms. Salt sensitivity has been more frequently observed in black people
than white people and hypertensive persons than normotensive persons [27,28]. Therefore, races and
individuals’ circumstance should be considered in salt intake and gene interaction studies [29,30]. In
the current study, FGF5 rs16998073 and PRDM8-FGF5 rs12509595 were significantly associated with an
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increased risk of hypertension both in participants with sodium intake < 2 g/day and in those with
intake ≥2 g/day. FGF5 rs16998073 was a well noted polymorphism in the largest GWAS performed by
the Global Blood Pressure Genetics Consortium [31]. FGF5, a member of the fibroblast growth factor
family, stimulates cell growth and proliferation of cardiac myocytes and promotes angiogenesis [32].
The association between FGF5 rs16998073 and hypertension was also recapitulated in a study of East
Asians [33], and this polymorphism was shown to be associated with salt sensitivity in Koreans [34].
NT52C rs1191582, ATP2B1-LINC00936 rs11105378, and CNNM2-NT5C2 rs140473396 were
significantly associated with decreased risk of hypertension, whether sodium intake was <2 or
≥2 g/day. NT52C rs11191582 is located in the gene-rich region near CYP17A1-CNNM2-NT5C2, which
in GWAS was reported to contain a number of regulatory polymorphisms related to CVD [35,36]. Our
study is the first to note the association of this polymorphism with hypertension. The association of
ATP2B1 rs11105378 with hypertension was reported in European, Japanese and Korean studies [37].
ATP2B1 encodes the plasma membrane calcium transporting ATPase isoform 1, which plays a
critical role in regulating blood pressure through alteration of intracellular calcium homeostasis and
vasoconstriction in vascular smooth muscle cells [37,38]. CNNM2-NT5C2 rs140473396 was recently
noted in a large, trans-ethnic study that included 776,078 participants from the Million Veteran Program,
and in collaborating studies to identify the common variants, rare variants, and genetically predicted
expression across multiple tissues of genes associated with blood pressure [39].
In the participants with sodium intake <2 g/day, we found significant association of rs67617923 in
EML6 with increased risk of hypertension. While associations of several genetic variants in EML6
(e.g., rs17046380, rs72806698) with hypertension have been noted previously [40], rs67617923 is a novel
genetic variant that was newly discovered in our study. Future studies to replicate this polymorphism
association, and efforts to uncover the role of EML6 in blood pressure, are needed.
In participants with sodium intake ≥2 g/day, C6orf10-HLA-DQB1 rs6913309, and RNF213
rs112735431 were associated with increased risk of hypertension. C6orf10-HLA-DQB1 rs6913309
is another novel genetic variant that this study has newly discovered. An allele of HLA-DQB1
(which encodes a class II molecule expressed in antigen-presenting cells) increases the production of
autoantibodies against angiotensin AT1 receptors, which was associated with essential hypertension in
Chinese patients [41]. However, the exact role of HLA-DQB1 remains unclear. Lie et al. [42] found that
the rs112735431 polymorphism of RNF213 was strongly associated with moyamoya disease in East
Asian populations, including Chinese, Japanese, and Korean. This polymorphism has also been found
to be related to intracranial artery steno-occlusive disease and moyamoya disease in Koreans [43].
The prevalence of moyamoya disease is 10 times higher in Japan and Korea than in Europe [44]. A
previous study, which investigated the moyamoya disease susceptibility polymorphisms, reported
that p.R4810K in RNF213 was found in the East Asian population but not in Southeast Asians [45].
Interestingly, the minor allele frequencies of the rs112735431 polymorphism were specified only in the
East Asian population and in the present study. Although the physiologic function of RNF213 is not yet
clear, previous studies found it to be involved in a novel signaling pathway in intracranial angiogenesis,
and in the proliferation and maintenance of endothelial cells [42,46]. Ohkubo et al. [47] suggested
that RNF213 promotes endothelial cell proliferation in response to inflammatory signals from the
environment. Excess salt intake promotes vasoconstriction by decreasing nitric oxide production
and increasing endothelial cell stiffness [48]. Furthermore, sodium intake is associated with systemic
inflammation [49]. We may assume that excess sodium intake could be a provoking factor for the
genetic effect of RNF213 on hypertension. Koizumi et al. [50] revealed that RNF213 was significantly
associated with high BP in Japanese populations. Park et al. [43] also reported that the proportion
of hypertension was higher in moyamoya diseases patients with the rs112735431 polymorphism of
RNF213 than in those with wild type. This Korean GWAS was the first to note the association of
this polymorphism with hypertension. Further studies to find association between the rs112735431
polymorphism in RNF213 and hypertension in other races/ethnicities are also needed.
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We also found GML-CYP11B1 rs3819496, MYL2-CUX2 rs12229654, and JAG1 rs1887320 to be
significantly associated with decreased risk of hypertension in participants with sodium intake ≥2
g/day. SNP rs3819496 represents a novel genetic variant, which was newly discovered in this study.
Although MYL2-CUX2 rs12229654 and its association with hypertension were first reported in this
study, a strong association of genetic variants of MYL2-CUX2 with high-density lipoprotein cholesterol
was shown in a Korean GWAS meta-analysis, and it was replicated in a BioBank Japan GWAS, Health 2,
and Shanghai Jiao Tong University cohort [51]. Another study conducted in Korea found that rs1229654
was also associated with dyslipidemia and diabetes [52]. Metabolic alteration due to rs1229654 might
lead to the development of hypertension. Interestingly, the frequency of this polymorphism was
determined only in the present study and in the East Asian population. Furthermore, persons carrying
mutations in MYL-2, encoding slow cardiac myosin regulatory light chain 2, developed hypertrophic
cardiomyopathy in the presence of hypertension or other risk factors for hypertrophy [53]. We may
cautiously assume that excess salt intake might be an additional risk factor for hypertension or CVD
in individuals with this genetic susceptibility. Association of JAG1 rs1887320 with hypertension and
CVD risk was reported in Chinese cohorts [54,55].
Our study has certain limitations. We investigated the hypertension-related SNPs according to
dietary sodium intake, as measured by FFQ. Although FFQ is a practical method to assess intake in
large cohort studies, such questionnaires use a limited list of food items and cannot accurately consider
additional salt intake via seasoning. Recall bias is another important limitation with FFQ. Second,
we could not exclude the possibility of secondary hypertension due to a lack of information about
it. Nevertheless, this is the first study to investigate hypertension-related SNPs according to sodium
intake in a large population-based study. The current study identified previously well-reported SNPs
related to hypertension. Furthermore, we identified several novel genetic variants associated with
hypertension according to sodium intake.
5. Conclusions
In this large population-based study, we identified genetic susceptibility differences between
participants whose sodium intake was less than 2 g/day and those whose intake was greater than 2
g/day. Discovering genetic predisposition for different sodium intakes would be helpful to establish
the individualized medical nutrition therapy for disease management, and better targeted public
health nutrition interventions. In further study, the effects and contributions of other confounding and
interaction factors such as smoking, alcohol, and environmental factors on hypertension should be
considered comprehensively.
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